IMC Immuron

Immuron Travelers’ Diarrhea Market Update

Immuron Travelers’ Diarrhea Market Update
EN
12/10/2020

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron IMM-529 IND approved by FDA

Immuron IMM-529 IND approved by FDA Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now active MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that ...

11h / 16m 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces Clinical Trial Update

Immuron Announces Clinical Trial Update IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (Clostridioides difficile infection)Immuron announced ...

October 31, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Q1 FY26 YoY growth

Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on pcp   Canada•Q1 sales AUD$0.0 million down 92% on pcp   USA•Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and th...

October 13, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Submits IMM-529 IND to FDA

Immuron Submits IMM-529 IND to FDA Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for clinical developm...

October 8, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Letter to Shareholders – Projects Update

Immuron Letter to Shareholders – Projects Update Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: The Australian Launch of ProIBS® is on track for ...

October 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch